Board of Directors
Chairman of the Board
Mr. Bihl has served on the Board since March 2008. Mr. Bihl is an experienced executive with more than 30 years in leadership of global healthcare businesses including a broad base of operational, financial, and senior executive positions. Mr. Bihl is currently the CEO of Bioventus LLC, a global provider of ortho biologic products, effective December 2, 2013. He also serves as a director on the board of Greatbatch Inc.. From 2011 to 2012, Mr. Bihl was Group President of American Medical Systems (“AMS”), a subsidiary of Endo Pharmaceuticals, in Minneapolis, Minnesota. From 2008 to 2011, Mr. Bihl was the President and Chief Executive Officer of AMS. From 2000 to 2007, Mr. Bihl served in various senior leadership positions at Bayer Healthcare Diagnostics Division including Vice President of Finance, Senior Vice President of Business Planning and Administration, and President, Diagnostics Division. Subsequently, he was Chief Executive Officer of Siemens DX upon the acquisition of Bayer’s Diagnostics Division by Siemens AG.
Dr. Walker joined Spectral as President and CEO in April 2001. Previously, he held the position of COO of the Toronto General Hospital, and was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.
A pioneer in the area of endotoxin and its role in sepsis, and the co-inventor of the Endotoxin Activity Assay (EAA™), Dr. Walker is a frequent participant at leading sepsis and critical care conferences, has been a keynote speaker at symposiums focusing on the role of endotoxin in sepsis, and is the author of over 100 scientific publications. He received his M.D. from the University of Western Ontario, his Ph.D. from the Salgrenska University of Göteborg, Sweden, and is a graduate of the Advanced Management Program from Harvard School of Business.
Mr. Giese has a B.A. in economics, a law degree, and an M.B.A. He has practiced law in Vancouver, was president of Mr. Lube U.S. (acquired by Pennzoil), was a director and CFO of TSX-listed NQL Drilling Tools (acquired by National Oilwell Varco), and has sat in management roles and on the board of directors of a number of private and other TSX listed companies. He is a past advisory board member of the Institute of Corporate Directors (Canada) and is currently a member of the Board of Directors of BioAlberta. Kevin Giese is the founding President, CEO and Director of Medwell Capital Corp. (formerly BioMS Medical Corp.), a biotechnology company dedicated to the development and commercialization of innovative therapies, with an emphasis on the treatment of Multiple Sclerosis. In 2005 he received the BioAlberta Award for Entrepreneurship.
Mr. Herrera is a seasoned global healthcare executive with more than 30 years of experience. Mr. Herrera is the Chairman and founder of Pinnacle Biologics Inc. Previously, Mr. Herrera spent 24 years at Abbott Laboratories, most recently serving as Senior Vice President, International Operations and President of Abbott International. In this role, Mr. Herrera was accountable for international commercial operations including sales and marketing of pharmaceutical, nutritional and hospital products in markets outside the US. In 2004, Mr. Herrera joined Rosetta Partners LLC as the Partner and Principal in charge of the private equity division. Mr. Herrera received a B.A. in industrial economics from the Universidad del Valle, Colombia, and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Mr. Takeshita has been Director, Medical Device Division of Toray Industries, Inc. since 2010. Mr. Takeshita joined Toray in 1983 and has over 20 years of experience in the clinical development of pharmaceutical products and medical devices. He was also a Technical Representative of Toray in its European Headquarters in London from 1991 to 1996. Mr. Takeshita received a bachelor's degree in pharmaceutical science from the University of Tokyo.
Mr. Woollard has degrees in pharmacy and pharmaceutical science, passing the Pharmaceutical Examining Board of Canada examinations in 1983, and in law, having become a member of the Alberta Bar in 1987. He has been corporate counsel and has practiced in the field of technology commercialization since 1990, joining the University of Alberta in 1994. He has served on the board of directors of six for-profit corporations. Mr. Woollard has been lead independent director of Medwell Capital Corp. (formerly BioMS Medical Corp.) since 2005 and is also chairman of the corporate governance committee, member of the compensation committee and past chairman of the audit and compensation committee.